Radioligand therapy with177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use.
Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. Electronic address: Hojjat.ahmadzadehfar@ukb.uni-bonn.de.
Hojjat
H
Ahmadzadehfar
Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Markus
M
Essler
Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Michael
M
Schäfers
Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Kambiz
K
Rahbar
D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary*
C000610110:Pluvicto; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; D008187:Lutetium; D017430:Prostate-Specific Antigen